Category: Allergan Inc.Syndicate content

Allergan accused of paying kickbacks to spur eye drug sales | MassDevice.com On Call

December 19, 2013 by Arezu Sarvestani

A False Claims Act lawsuit unsealed this week accuses aesthetics devices maker Allergan of handing out kickbacks to get doctors to prescribe the company's eye drugs.

MassDevice.com On Call

MASSDEVICE ON CALL — A pair of Philadelphia ophthalmologists accused medtech company Allergan (NYSE:AGN) of offering doctors illegal kickbacks in exchange for prescriptions of the Allergan's eye drugs.

Celebrities, Botox and bad advice | MassDevice.com On Call

December 18, 2013 by Arezu Sarvestani

Celebrity medical advice, like the recent backlash against Allergan's Botox cosmetic injections, can have major repercussions for patients and for the healthcare industry, even when the advice is bad.

MassDevice.com On Call

MASSDEVICE ON CALL — A pair of reports this week examined the repercussions of celebrity medical advice, from the recent backlash against Botox aesthetic facial injections to actress Jennie McCarthy's avid repudiation of vaccines.

Obesity: Allergan finalizes Lap-Band division sale

December 3, 2013 by Arezu Sarvestani

Apollo Endosurgery closes the books on its acquisition of Allergan's obesity intervention business, including the Lap-Band and Orbera technologies, in a deal worth up to $110 million.

Allergan finalizes Lap-Band division sale

Medtech company Allergan (NYSE:AGN) officially dumped its obesity interventions business, consummating with Apollo Endosurgery a deal worth up to $110 million.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Apollo Endosurgery to buy Allergan's obesity biz for up to $110M

October 29, 2013 by Brad Perriello

Apollo Endosurgery inks a deal with Allergan to acquire its obesity intervention business for up to $110 million.

Apollo Endosurgery to buy Allergan's obesity biz for up to $110M

Almost exactly 1 year after saying it would seek a buyer for its Lap-Band obesity device, Allergan (NYSE:AGN) said today that Apollo Endosurgery agreed to spend up to $110 million on Allergan's obesity intervention business, which includes the Orbera intra-gastric balloon.

Aesthetic: Allergan lands FDA win for Juvederm facial filler

October 23, 2013 by Arezu Sarvestani

FDA regulators grant premarket approval to Allergan's Juvederm Voluma XC injectable gel for aesthetic volume restoration in the face.

Allergan lands FDA win for Juvederm facial filler

Aesthetics company Allergan (NYSE:AGN) notched a U.S. market 1st with FDA approval for its Juvederm Voluma XC facial filler, the only filler indicated for age-related volume restoration in the cheeks.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

CEO Insight: Stemming the tide of illegal importation and counterfeiting

August 26, 2013 by MassDevice

Allergan board chairman and CEO David Pyott on the "tide" of illegally imported drugs and medical devices.

David Pyott

By David Pyott

The tide of counterfeit and illegally imported drugs and medical devices continues to be strong, as difficult economic times drives demand for seemingly cheaper alternatives. The sophistication of the counterfeiters and illegal importers makes this an increasingly difficult battle to wage, but the threat these illegally imported drugs pose to consumers is real, making it essential that government agencies, with support from industry, continue efforts to help battle this issue.

Allergan's Q2 sales, profits rise

July 31, 2013 by Brad Perriello

Allergan beats Wall Street's forecast for its 2nd-quarter results, with a 7.4% increase for its medical device segment.

Allergan's Q2 sales, profits rise

Allergan (NYSE:AGN) shares ticked up today on strong 2nd-quarter sales and earnings numbers, including a 7.4% top-line gain for its medical device segment.

Irvine, Calif.-based Allergan reported profits of $359.9 million, or $1.17 per share, on sales of $1.60 billion for the 3 months ended June 30, for bottom-line growth of 21.8% on sales growth of 10.2%.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp